Source - RNS
RNS Number : 6992J
Hutchison China Meditech Limited
30 June 2017
 

Total Voting Rights



London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 60,737,204 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

 

For illustrative purposes only, the 60,737,204 ordinary shares would be equivalent to 60,737,204 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,474,408 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

 

 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries



Christian Hogg, CEO

+852 2121 8200





U.K. & International Media Enquiries



Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

[email protected]




U.S. Based Media Enquiries



Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

[email protected]

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

[email protected]




Investor Relations



Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

[email protected]

David Dible, Citigate Dewe Rogerson 

+44 7967 566 919 (Mobile)

[email protected]




Panmure Gordon (UK) Limited



Richard Gray / Andrew Potts

+44 (20) 7886 2500


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREASKEDLDXEEF